Breathe Well Live Well
 Citybizlist |
Targacept CEO steps down, leaves board
BusinessWeek The departure comes as the company has slashed its work force to cut costs after ending development of an experimental depression drug and setbacks in tests of another drug to treat asthma and diabetes. Its shares are down more than 80 percent in the … Biopharma company Targacept says CEO resigns Targacept's CEO stepping down in reshuffle |
View full post on asthma – Google News
Citybizlist |
Targacept CEO steps down, leaves board
Boston.com The departure comes as the company has slashed its work force to cut costs after ending development of an experimental depression drug and setbacks in tests of another drug to treat asthma and diabetes. Its shares are down more than 80 percent in the … Targacept's CEO stepping down in reshuffle Biopharma company Targacept says CEO resigns Don deBethizy resigns as Targacept CEO |
View full post on asthma – Google News
 Citybizlist |
Targacept: Drug missed goal due to analysis error
BusinessWeek Drug developer Targacept Inc. said Tuesday that further analysis showed an experimental asthma treatment failed one one of its goals in a clinical trial, contrary to what the company previously reported. Targacept shares lost 59 cents, or 12.2 percent, … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of … Targacept reports error in asthma study Targacept loses big shareholder, finds error in previous study |
View full post on asthma – Google News
|
UPDATE Targacept loses big shareholder, finds error in previous study
Winston-Salem Journal (blog) Targacept Inc.'s rollercoaster ride – financially and in research – dropped again today with the news that a recent asthma study did not perform as first stated on March 27. The company, based in Winston-Salem, also learned in a regulatory filing … |
View full post on asthma – Google News
|
Targacept loses big shareholder, finds error in previous study
Winston-Salem Journal Targacept Inc.'s rollercoaster ride – financially and in research – dropped again today with the news that a recent asthma study did not perform as first stated on March 27. The company, based in Winston-Salem, also learned in a regulatory filing … |
View full post on asthma – Google News
|
Targacept reports error in asthma study
Triad Business Journal Targacept disclosed an error in the analysis of a potential asthma treatment, but says the candidate still holds promise. Targacept said an error in the analysis of a drug it recently studied as a potential treatment for asthma affected the results, … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of … Targacept Revises Results Of Exploratory Drug Study; Shares Slump Targacept Reports Revised Top-Line Results From Phase 2 Study Of TC-6987 |
View full post on asthma – Google News
|
Targacept Reports Revised Top-Line Results From Phase 2 Study Of TC-6987
NASDAQ (RTTNews.com) – Targacept Inc. (TRGT) announced revised top-line results from its exploratory Phase 2 clinical study of TC-6987 in asthma. After identifying an error in the application of the agreed statistical analysis plan, a reanalysis of the data … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study |
View full post on asthma – Google News
|
Targacept slips on mixed results from drug studies
BusinessWeek Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were treated with TC-6987 for … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … Targacept discontinues two clinical trials, reports success with a third Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials |
View full post on asthma – Google News
|
Targacept says drug candidate worked as an asthma treatment, but fails as …
Greenfield Daily Reporter AP WINSTON-SALEM, NC — Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials Targacept reports mixed data from two trials |
View full post on asthma – Google News
|
Targacept says drug candidate worked as an asthma treatment, but fails as …
The Republic AP WINSTON-SALEM, NC — Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials Targacept reports mixed data from two trials |
View full post on asthma – Google News